Data Insights

CT-023 by Shenzhen Xiankangda Life Sciences for Breast Cancer: Likelihood of Approval

CT-023 is under clinical development by Shenzhen Xiankangda Life Sciences and currently in Phase I for Breast Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - CT-023 in Breast Cancer

Data Insights

CT-023 by Shenzhen Xiankangda Life Sciences for Lung Cancer: Likelihood of Approval

CT-023 is under clinical development by Shenzhen Xiankangda Life Sciences and currently in Phase I for Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - CT-023 in Lung Cancer

Data Insights

CT-023 by Shenzhen Xiankangda Life Sciences for Ovarian Cancer: Likelihood of Approval

CT-023 is under clinical development by Shenzhen Xiankangda Life Sciences and currently in Phase I for Ovarian Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - CT-023 in Ovarian Cancer

Data Insights

CT-023 by Shenzhen Xiankangda Life Sciences for Prostate Cancer: Likelihood of Approval

CT-023 is under clinical development by Shenzhen Xiankangda Life Sciences and currently in Phase I for Prostate Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - CT-023 in Prostate Cancer

Data Insights

CT-023 by Shenzhen Xiankangda Life Sciences for Colorectal Cancer: Likelihood of Approval

CT-023 is under clinical development by Shenzhen Xiankangda Life Sciences and currently in Phase I for Colorectal Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - CT-023 in Colorectal Cancer

Data Insights

CT-023 by Shenzhen Xiankangda Life Sciences for Cervical Cancer: Likelihood of Approval

CT-023 is under clinical development by Shenzhen Xiankangda Life Sciences and currently in Phase I for Cervical Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - CT-023 in Cervical Cancer

Data Insights

CT-023 by Shenzhen Xiankangda Life Sciences for Pancreatic Cancer: Likelihood of Approval

CT-023 is under clinical development by Shenzhen Xiankangda Life Sciences and currently in Phase I for Pancreatic Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - CT-023 in Pancreatic Cancer

Data Insights

CT-023 by Shenzhen Xiankangda Life Sciences for Gastric Cancer: Likelihood of Approval

CT-023 is under clinical development by Shenzhen Xiankangda Life Sciences and currently in Phase I for Gastric Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - CT-023 in Gastric Cancer

Data Insights

CT-023 by Shenzhen Xiankangda Life Sciences for Solid Tumor: Likelihood of Approval

CT-023 is under clinical development by Shenzhen Xiankangda Life Sciences and currently in Phase I for Solid Tumor. According to...

Likelihood of Approval and Phase Transition Success Rate Model - CT-023 in Solid Tumor

Data Insights

CT-023 by Shenzhen Xiankangda Life Sciences for Endometrial Cancer: Likelihood of Approval

CT-023 is under clinical development by Shenzhen Xiankangda Life Sciences and currently in Phase I for Endometrial Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - CT-023 in Endometrial Cancer

Data Insights

CT-023 by Shenzhen Xiankangda Life Sciences for Thyroid Cancer: Likelihood of Approval

CT-023 is under clinical development by Shenzhen Xiankangda Life Sciences and currently in Phase I for Thyroid Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - CT-023 in Thyroid Cancer

Data Insights

CT-023 by Shenzhen Xiankangda Life Sciences for Esophageal Cancer: Likelihood of Approval

CT-023 is under clinical development by Shenzhen Xiankangda Life Sciences and currently in Phase I for Esophageal Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - CT-023 in Esophageal Cancer